We are live on ! Find out more

Cognition Therapeutics

CGTX

Market cap $97M

1.02 USD

-0.04

3.77%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

1.00

-0.02

1.96%

1 day

-3.77%

5 days

3.03%

1 month

10.45%

3 months

-14.29%

6 months

-3.77%

Year to date

-30.61%

1 year

-58.87%

5 years

-92.01%

10 years

-92.01%

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Employees: 14

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 85.7%

Negative 14.3%

Zacks Investment Research

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Cognition Therapeutics Participating in Upcoming Investor Conferences

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company's plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition's website.

Cognition Therapeutics Participating in Upcoming Investor Conferences

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026.

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™